Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Provider Reforms Gaining Momentum In Congress

Executive Summary

House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.

You may also be interested in...



Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing

Getting seven top pharma leaders in the same room, required to answer tough questions on drug pricing, is rare. Members of the Senate Finance Committee got that opportunity recently, but there are some questions our Pink Sheet reporters think they missed.

340B Reform: US House Bills Mark The End Of The Beginning

Energy & Commerce Health Subcommittee releases several discussion drafts at hearing on 340B drug discount program reform as the debate seems poised to move into the next phase.

Many 340B Providers May Not Pass On Discounts Through Contract Pharmacies – GAO

House Energy and Commerce Committee releases US Government Accountability Office analysis of 340B contract pharmacies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS122293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel